ALGLUCERASE - A REVIEW OF ITS THERAPEUTIC USE IN GAUCHERS-DISEASE

被引:27
作者
WHITTINGTON, R
GOA, KL
机构
[1] Adis International Limited, Auckland, 41 Centorian Drive, Mairangi Bay
关键词
D O I
10.2165/00003495-199244010-00007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Alglucerase is a mannose-terminated form of human placental glucocerebrosidase, developed to treat patients with Gaucher's disease. Functional glucocerebrosidase is deficient in Gaucher's disease, an autosomal recessive lipid storage disorder that affects people of all ethnic backgrounds, but has a higher incidence among East European Jews (Ashkenazim). Gaucher's disease manifests with hepatosplenomegaly, bleeding disorders and bone disease, with the more rare subtypes (types 2 and 3) featuring neurological dysfunction. Prior to the development of enzyme replacement therapy, treatment for Gaucher's disease was mainly symptomatic relief Primary treatment with glucocerebrosidase focuses on removal of the lipid metabolite that causes the pathology. Because of the rarity of Gaucher's disease clinical trials are small, and much of the data investigating alglucerase therapy have been obtained from studies of patients with type 1 disease, the prevalent subtype. Nonetheless, after intravenous administration of alglucerase, improvements are evident within 6 months of therapy. Patients have increased haemoglobin levels and platelet counts, and decreased incidences of epistaxis and bruising. Spleen and liver size are reduced, and skeletal parameters improve. Children gain height and most patients receiving alglucerase therapy are able to resume work and daily activities. Alglucerase is well tolerated, with few mild adverse reactions reported. Although the pharmacokinetic and pharmacodynamic information for alglucerase is limited, its unequivocal efficacy justifies enzyme replacement therapy with this compound as first-line treatment for patients with Gaucher's disease, for whom treatment options are limited.
引用
收藏
页码:72 / 93
页数:22
相关论文
共 91 条
  • [1] CONDITIONS AFFECTING THE ACTIVITY OF GLUCOCEREBROSIDASE PURIFIED FROM SPLEENS OF CONTROL SUBJECTS AND PATIENTS WITH TYPE-1 GAUCHER DISEASE
    AERTS, JMFG
    MIRANDA, MCS
    BROUWERKELDER, EM
    VANWEELY, S
    BARRANGER, JA
    TAGER, JM
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1041 (01) : 55 - 63
  • [2] DEFICIENT ACTIVITY OF GLUCOCEREBROSIDASE IN URINE FROM PATIENTS WITH TYPE-1 GAUCHER DISEASE
    AERTS, JMFG
    DONKERKOOPMAN, WE
    KOOT, M
    BARRANGER, JA
    TAGER, JM
    SCHRAM, AW
    [J]. CLINICA CHIMICA ACTA, 1986, 158 (02) : 155 - 163
  • [3] COMPARATIVE-STUDY ON GLUCOCEREBROSIDASE IN SPLEENS FROM PATIENTS WITH GAUCHER DISEASE
    AERTS, JMFG
    DONKERKOOPMAN, WE
    BRUL, S
    VANWEELY, S
    MIRANDA, MCS
    BARRANGER, JA
    TAGER, JM
    SCHRAM, AW
    [J]. BIOCHEMICAL JOURNAL, 1990, 269 (01) : 93 - 100
  • [5] Barranger J. A., 1989, METABOLIC BASIS INHE, P1677
  • [6] BARRANGER JA, 1989, JPN J INHERIT METAB, V51, P45
  • [7] DOSE-DEPENDENT RESPONSES TO MACROPHAGE-TARGETED GLUCOCEREBROSIDASE IN A CHILD WITH GAUCHER DISEASE
    BARTON, NW
    BRADY, RO
    DAMBROSIA, JM
    DOPPELT, SH
    HILL, SC
    HOLDER, CA
    MANKIN, HJ
    MURRAY, GJ
    ZIRZOW, GC
    PARKER, RI
    [J]. JOURNAL OF PEDIATRICS, 1992, 120 (02) : 277 - 280
  • [8] REPLACEMENT THERAPY FOR INHERITED ENZYME DEFICIENCY - MACROPHAGE-TARGETED GLUCOCEREBROSIDASE FOR GAUCHERS-DISEASE
    BARTON, NW
    BRADY, RO
    DAMBROSIA, JM
    DIBISCEGLIE, AM
    DOPPELT, SH
    HILL, SC
    MANKIN, HJ
    MURRAY, GJ
    PARKER, RI
    ARGOFF, CE
    GREWAL, RP
    YU, KT
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (21) : 1464 - 1470
  • [9] THERAPEUTIC RESPONSE TO INTRAVENOUS INFUSIONS OF GLUCOCEREBROSIDASE IN A PATIENT WITH GAUCHER DISEASE
    BARTON, NW
    FURBISH, FS
    MURRAY, GJ
    GARFIELD, M
    BRADY, RO
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (05) : 1913 - 1916
  • [10] BARTON NW, 1991, HEMATOLOGICAL RESPON